ClinVar Miner

Submissions for variant NM_015450.3(POT1):c.255+1G>A

dbSNP: rs1584777699
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000801661 SCV000941449 likely pathogenic Tumor predisposition syndrome 3 2023-10-15 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 7 of the POT1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with multiple primary melanoma (PMID: 32325837; Invitae). ClinVar contains an entry for this variant (Variation ID: 647206). Studies have shown that disruption of this splice site results in skipping of exon 7 and introduces a premature termination codon (PMID: 32325837). The resulting mRNA is expected to undergo nonsense-mediated decay. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Ambry Genetics RCV002424851 SCV002742947 likely pathogenic Hereditary cancer-predisposing syndrome 2021-05-11 criteria provided, single submitter clinical testing The c.255+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 3 of the POT1 gene. This variant was identified in 1/167 Italian individuals with cutaneous melanoma who were CDKN2A/ARF- and CDK4-negative. RNA studies demonstrated that this alteration leads to skipping of coding exon 3 (Pastorino L et al. Cancers (Basel). 2020 04;12:). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.